scholarly journals A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck – the RESGEX study

ESMO Open ◽  
2021 ◽  
Vol 6 (5) ◽  
pp. 100242
Author(s):  
K. Klinghammer ◽  
J. Fayette ◽  
A. Kawecki ◽  
A. Dietz ◽  
P. Schafhausen ◽  
...  
Keyword(s):  
Head And Neck ◽  
Phase Ii ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Phase Ii Study ◽  
Cell Cancer ◽  
Efficacy And Safety ◽  
Randomized Phase Ii ◽  
Egfr Antibody

scholarly journals Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer

2017 ◽  
Vol 22 (7) ◽  
pp. 782 ◽  
Author(s):  
Marco Siano ◽  
Francesca Molinari ◽  
Vittoria Martin ◽  
Nicolas Mach ◽  
Martin Früh ◽  
...  
Keyword(s):  
Head And Neck ◽  
Phase Ii ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Phase Ii Study ◽  
Cell Cancer ◽  
Advanced Head ◽  
Multicenter Phase ◽  
Neck Squamous Cell Cancer
Sign in / Sign up

Export Citation Format

Share Document